RecruitingNCT07177742

Prospective Cohort Study on the Relationship Between Exosomal Peroxiredoxin 1 (PRDX1) and Postoperative Liver Metastasis

Prospective Cohort Study on the Relationship Between Peroxiredoxin 1 (PRDX1) in Blood Exosomes From Colorectal Cancer Radical Resection Specimens and Postoperative Liver Metastasis


Sponsor

Mu-qing Yang

Enrollment

260 participants

Start Date

Feb 15, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

The occurrence of liver metastasis after curative surgery for resectable colorectal cancer is an important cause of death for patients. Accurately identifying high-risk patients for metastasis and intervening in them has important clinical significance. The pathological examination of surgical specimens failed to fully utilize valuable specimen information and accurately predict liver metastasis; The biomarkers secreted by tumors are metabolized in the liver through the portal vein, especially the particles such as extracellular vesicles secreted by tumors, which are ultimately diluted in peripheral blood and cannot be effectively detected. Our research group extracted an average of 11.25ml of blood (named blood derived from portal vein branch specimens, sdBlood for short) from 8 colorectal cancer radical surgery specimens. Compared with peripheral blood, protein mass spectrometry analysis revealed a significant increase in exosome proteins such as peroxidized redox protein 1 (PRDX1), which are highly correlated with metastasis. This project innovatively uses sdBlood, which has been overlooked by routine pathological examination, to detect the exosomal protein PRDX1 in sdBlood, which is significantly higher than the peripheral blood concentration. A prospective cohort study was established, including 252 patients with pathologically confirmed colorectal cancer after radical surgery. The incidence and time of liver metastasis were followed up and observed. Cox regression statistical analysis was used to determine the correlation between this marker and metastasis and determine its critical value, providing a basis for clinical diagnosis and treatment.


Eligibility

Min Age: 19 MonthsMax Age: 80 Months

Plain Language Summary

Simplified for easier understanding

This study is investigating whether a protein called PRDX1 (peroxiredoxin 1) found in tiny particles in the blood (called exosomes) can predict whether colon cancer will spread to the liver after surgery. Identifying this biomarker early could help doctors monitor patients more closely. **You may be eligible if...** - You are between 19 and 80 years old - You have been diagnosed with colon adenocarcinoma (a type of colon cancer) confirmed by pathology - You have completed curative (radical) surgery for colorectal cancer - You are able to attend scheduled follow-up visits and comply with study procedures - You have signed an informed consent form **You may NOT be eligible if...** - Your cancer cannot be fully removed with surgery - You have a pre-existing liver disease (such as hepatitis B/C, severe fatty liver, or cirrhosis) - You required removal of other organs during surgery (combined organ resection) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERObservation

Observation.


Locations(1)

Shanghai Tongji Hospital, Hepatobilliary Surgery Center, Tongji University

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07177742


Related Trials